EMA seeks to issue guidance on liver damage from Novartis’s gene therapy
The statement follows recent deaths due to liver failure after treatment with the gene therapy, the EMA said
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Zolgensma
Biogen to study Spinraza in combination with $2-mn Novartis drug
The one-a-day oral drug is viewed as a potential a rival to Spinraza, which is administered every four months via spinal infusion
Roche’s SMA drug trial win bolsters $2 billion sales prospects
US regulators are due to decide by May 24
Novartis’ Zolgensma study halted by FDA amid safety questions
The US Food and Drug Administration's partial hold on the so-called STRONG trial impacts patients aged up to five with spinal…